Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RAGE

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  Next»
    Study title: Action antipyrétique de l'acétylsalicylate de lysine (essai comparatif randomisé de trois posologies chez le jeune enfant) - JC Rolland, J. Papoin, C. Maurage, B. Caurier-1986 - Publication in the report N° FILIRF-FRZ0069-EN-E01 -
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46165
    Study title: Action antipyrétique de l'acétylsalicylate de lysine (essai comparatif randomisé de trois posologies chez le jeune enfant) - JC Rolland, J. Papoin, C. Maurage, B. Caurier-1986 - Publication in the expert report on the clinical documentation - P. Grippon - 12 Nov 1991 -
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46179
    Study title: Anwendungsbeobachtung zu Wirksamkeit und Verträglichkeit von Imupret Tropfen oder Dragees zur Behandlung von rezidivierenden Atemwegserkrankungen bei Kindern und Jugendlichen
    Active substance: alcoholic-aqueous extract (extracting agent: ethanol 59 vol. %) derived from marshmallow root chamomile flowers horstail herb walnut leaves yarrow herb oak bark dandelion herb
    Study summary document link (including results):
    View full study record
    Document reference: 39777
    Study title: Anwendungsbeobachtung zu Wirksamkeit und Verträglichkeit von Imupret Tropfen oder Dragees zur Behandlung von rezidivierenden Atemwegserkrankungen bei Kindern und Jugendlichen
    Active substance: aqueous extract (extracting agent: ethanol 59 % ), 0.4 g marshmallow root (Althaeae radix), 0.4 g walnut leaves (Juglandis folia), 0.3 g chamomile flowers (Chamomillae flores), 0.5 g horsetail herb (Equiseti herba), 0.4 g common yarrow (Achillea millefolium), 0.2 g oak bark (Quercus cortex), 0.4 g dandelion herb (Taraxaci herba).
    Study summary document link (including results):
    View full study record
    Document reference: 39795
    Study title: Burlina-A-B, Dermikol-M, Mantau-A, Piovan-S, Grazian-L, Zacchello-F, Shin-Y. Department of Pediatrics, University of Padova, Italy. Increased plasma biotinidase activity in patients with glycogen storage disease type Ia: effect of biotin supplementation. Journal of inherited metabolic disease, {J-Inherit-Metab-Dis}, 1996, vol. 19, no. 2, p. 209-12, ISSN: 0141-8955.Burlina-A-B, Dermikol-M, Mantau-A, Piovan-S, Grazian-L, Zacchello-F, Shin-Y. Department of Pediatrics, University of Padova, Italy. Increased plasma biotinidase activity in patients with glycogen storage disease type Ia: effect of biotin supplementation. Journal of inherited metabolic disease, {J-Inherit-Metab-Dis}, 1996, vol. 19, no. 2, p. 209-12, ISSN: 0141-8955.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22618
    Study title: Nothjunge-J, Krageloh-Mann-I, Suormala-T-M, Baumgartner-E-R. Abteilung Allgemeine Padiatrie, Universitats-Kinderklinik, Tubingen, Germany. Biotinidase deficiency: A hereditary metabolic disorder successfully treated with biotin. Monatsschrift fur Kinderheilkunde {MONATSSCHR-KINDERHEILKD}, 1989, Vol/Iss/Pg. 137/11 (737-740), ISSN: 0026-9298.Nothjunge-J, Krageloh-Mann-I, Suormala-T-M, Baumgartner-E-R. Abteilung Allgemeine Padiatrie, Universitats-Kinderklinik, Tubingen, Germany. Biotinidase deficiency: A hereditary metabolic disorder successfully treated with biotin. Monatsschrift fur Kinderheilkunde {MONATSSCHR-KINDERHEILKD}, 1989, Vol/Iss/Pg. 137/11 (737-740), ISSN: 0026-9298.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22634
    Study title: Usefulness of Bisacodyl dragees for preparation of patients for radiographic procedures
    Active substance: BISACODYL
    Study summary document link (including results):
    View full study record
    Document reference: 22711
    Study title: Ozen H, Ciliv G, Koçak N, Saltik IN, Yüce A, Gürakan F. Short-term effect of captopril on microalbuminuria in children with glycogen storage disease type Ia. J Inherit Metab Dis. 2000 Jul;23(5):459-63. PMID: 10947200 [PubMed - indexed for MEDLINE]Ozen H, Ciliv G, Koçak N, Saltik IN, Yüce A, Gürakan F. Short-term effect of captopril on microalbuminuria in children with glycogen storage disease type Ia. J Inherit Metab Dis. 2000 Jul;23(5):459-63. PMID: 10947200 [PubMed - indexed for MEDLINE]
    Active substance: CAPTOPRIL
    Study summary document link (including results):
    View full study record
    Document reference: 23229
    Study title: Examination of the cariogenic effect of repeated intake of sucrose-containing beverage and prevention by fluoride containing varnishes
    Active substance: CALCIUM FLUORIDE AND SODIUM FLUORIDE
    Study summary document link (including results): Report-Bifluorid 12_Plaque screening_QLF inspector_english.pdf
    View full study record
    Document reference: 23182
    Study title: A Multicenter, Randomized, Controlled Trial of Celsior for Flush and Hypothermic Storage of Cardiac AllograftsVega 2001
    Active substance: CELSIOR
    Study summary document link (including results): Vega 2001.pdf
    View full study record
    Document reference: 48355
    Study title: Packer RJ et al Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8Packer RJ et al Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25051
    Study title: Packer RJ et al Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8Packer RJ et al Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25052
    Study title: DIECKMANN-K, MAURAGE-C, ROLLAND-J-C, RAMPONI-N, JONVILLE-A-P, ET-AL. CHU CLOCHEVILLE, TOURS, FRANCE. TORTICOLLIS AS A SIDE EFFECT OF CISAPRIDE TREATMENT IN AN INFANT. JOURNAL-OF-PEDIATRIC-GASTROENTEROLOGY-AND-NUTRITION (J-PEDIATR- GASTROENTEROL-NUTR). 22: 336-337, APR 1996.DIECKMANN-K, MAURAGE-C, ROLLAND-J-C, RAMPONI-N, JONVILLE-A-P, ET-AL. CHU CLOCHEVILLE, TOURS, FRANCE. TORTICOLLIS AS A SIDE EFFECT OF CISAPRIDE TREATMENT IN AN INFANT. JOURNAL-OF-PEDIATRIC-GASTROENTEROLOGY-AND-NUTRITION (J-PEDIATR- GASTROENTEROL-NUTR). 22: 336-337, APR 1996.
    Active substance: TRIMEBUTINE
    Study summary document link (including results):
    View full study record
    Document reference: 46755
    Study title: CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC ACTIVITY AND TOLERABILITY OF ANAFRANIL 10MG DRAGEES IN CHILDREN SUFFERING FROM DEPRESSION, ANOREXIA, ENURESIS, SCHOOL-PHOBIA, PHOBIA AND OBSESSION OR ANXIETY
    Active substance: CLOMIPRAMINE
    Study summary document link (including results):
    View full study record
    Document reference: 24388
    Study title: Coverage and cost of iodized oil capsule distribution in Tanzania. ;Peterson-S. Health Policy and Planning, 1999, Vol/Iss/Pg. 14 /4 (390-399)Coverage and cost of iodized oil capsule distribution in Tanzania. ;Peterson-S. Health Policy and Planning, 1999, Vol/Iss/Pg. 14 /4 (390-399)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30226
    Study title: Am J Cardiol. 1996 Jul 15;78(2):175-81. Evaluation of myocardial ischemia and infarction by signal-averaged electrocardiographic late potentials in children with Kawasaki disease. Ogawa S, Nagai Y, Zhang J, Yuge K, Hino Y, Jimbo O, Fukazawa R, Hayashi RAm J Cardiol. 1996 Jul 15;78(2):175-81. Evaluation of myocardial ischemia and infarction by signal-averaged electrocardiographic late potentials in children with Kawasaki disease. Ogawa S, Nagai Y, Zhang J, Yuge K, Hino Y, Jimbo O, Fukazawa R, Hayashi R
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44508
    Study title: Wirksamkeit und Vertraeglichkeit von Rytmonorm 10 mg, Dragees, bei Kindern - Ergebnisse einer multizentrischen Studie - (Efficacy and safety of Rytmonorm 10 mg sugar-coated tablets in children - Results of a multicentre study -)
    Active substance: PROPAFENONE
    Study summary document link (including results): propafenone-m03681.pdf
    View full study record
    Document reference: 35059
    Study title: THE NECESSITY FOR GRAM NEGATIVE ANTIMICROBIAL COVERAGE IN THE PREVENTION OF INFECTION FOLLOWING HEAD AND NECK SURGERY
    Active substance: SULBACTAM
    Study summary document link (including results):
    View full study record
    Document reference: 42628
    Study title: Clin Nucl Med. 1988 Apr;13(4):286-90. Experience with thallium-201 imaging in head and neck cancer. el-Gazzar AH, Sahweil A, Abdel-Dayem HM, Kubasik H, Halker R, Hassan IM, Jamil M, Rageb A, Abdul-Rahim SM, Mahmoud A, et al. Clin Nucl Med. 1988 Apr;13(4):286-90. Experience with thallium-201 imaging in head and neck cancer. el-Gazzar AH, Sahweil A, Abdel-Dayem HM, Kubasik H, Halker R, Hassan IM, Jamil M, Rageb A, Abdul-Rahim SM, Mahmoud A, et al.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44541
    Study title: Packer RJ et al Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8Packer RJ et al Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32232
    1  2  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 05:25:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA